JNJ

237.78

+1.48%↑

UNH

268.4

-2.59%↓

TMO

542.28

-3.73%↓

ABT

109.09

+0.87%↑

ISRG

476.03

-0.43%↓

JNJ

237.78

+1.48%↑

UNH

268.4

-2.59%↓

TMO

542.28

-3.73%↓

ABT

109.09

+0.87%↑

ISRG

476.03

-0.43%↓

JNJ

237.78

+1.48%↑

UNH

268.4

-2.59%↓

TMO

542.28

-3.73%↓

ABT

109.09

+0.87%↑

ISRG

476.03

-0.43%↓

JNJ

237.78

+1.48%↑

UNH

268.4

-2.59%↓

TMO

542.28

-3.73%↓

ABT

109.09

+0.87%↑

ISRG

476.03

-0.43%↓

JNJ

237.78

+1.48%↑

UNH

268.4

-2.59%↓

TMO

542.28

-3.73%↓

ABT

109.09

+0.87%↑

ISRG

476.03

-0.43%↓

Search

Cytek Biosciences Inc

Suletud

SektorTervishoid

4.5 -8.54

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

4.43

Max

4.93

Põhinäitajad

By Trading Economics

Sissetulek

105K

-5.5M

Müük

6.7M

52M

Aktsiakasum

-0

Kasumimarginaal

-10.476

Töötajad

692

EBITDA

6.4M

-4.2M

Soovitused

By TipRanks

Soovitused

Osta

12 kuu keskmine prognoos

+25.15% upside

Dividendid

By Dow Jones

Järgmine tulemuste avaldamine

26. veebr 2026

Turustatistika

By TradingEconomics

Turukapital

159M

660M

Eelmine avamishind

13.04

Eelmine sulgemishind

4.5

Uudiste sentiment

By Acuity

17%

83%

23 / 352 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Weak Bullish Evidence

Cytek Biosciences Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

5. veebr 2026, 23:57 UTC

Tulu

Naver Has Record Year Despite Weaker Final Quarter

5. veebr 2026, 23:45 UTC

Kuumad aktsiad

Stocks to Watch: Amazon, Coty, Gen Digital, Roblox

5. veebr 2026, 22:26 UTC

Tulu

REA Group Lifts Dividend, Announces Buyback as 1st Half Profit Rises 9% -- Update

5. veebr 2026, 22:00 UTC

Tulu

REA Group Lifts Dividend, Announces Buyback as 1st Half Profit Rises 9%

5. veebr 2026, 23:47 UTC

Market Talk

Global Equities Roundup: Market Talk

5. veebr 2026, 23:47 UTC

Market Talk

Nikkei May Fall After U.S. Tech Stock Drops -- Market Talk

5. veebr 2026, 23:43 UTC

Market Talk

Gold Falls on Spillover Impact From Cryptocurrencies' Selloff -- Market Talk

5. veebr 2026, 23:37 UTC

Market Talk

Glencore Shares Look Cheap After Failed Takeover Talks -- Market Talk

5. veebr 2026, 23:20 UTC

Tulu
Omandamised, ülevõtmised, äriostud

Amazon to Spend $200 Billion as It Accelerates AI Projects -- 5th Update

5. veebr 2026, 23:11 UTC

Market Talk

Amazon CEO Confident in Return on $200B Investment -- Market Talk

5. veebr 2026, 23:09 UTC

Tulu

Naver 2025 Net KRW1.820T Vs. Net KRW1.932T >035420.SE

5. veebr 2026, 23:08 UTC

Tulu

Naver 2025 Oper Pft KRW2.208T Vs. Pft KRW1.979T >035420.SE

5. veebr 2026, 23:07 UTC

Tulu

Naver 2025 Rev KRW12.035T Vs. KRW10.738T >035420.SE

5. veebr 2026, 23:03 UTC

Market Talk
Tulu

REA's Update Looks Negative Despite A$200M Buyback -- Market Talk

5. veebr 2026, 23:03 UTC

Tulu
Omandamised, ülevõtmised, äriostud

Bitcoin Booster's $12 Billion Loss Headlines Crypto's Worst Day Since 2022 Crash -- WSJ

5. veebr 2026, 23:00 UTC

Tulu

Naver 4Q Net Profit Missed FactSet-Compiled Consensus

5. veebr 2026, 23:00 UTC

Tulu

Naver 4Q Net KRW164.60B Vs. Net KRW514.00B >035420.SE

5. veebr 2026, 22:59 UTC

Tulu

Naver 4Q Oper Pft KRW610.60B Vs. Pft KRW542.00B >035420.SE

5. veebr 2026, 22:59 UTC

Tulu

Naver 4Q Rev KRW3.195T Vs. KRW2.886T >035420.SE

5. veebr 2026, 22:52 UTC

Tulu

Alphabet Stock Is Taking a Hit After Strong Earnings. Don't Panic. -- Barrons.com

5. veebr 2026, 22:45 UTC

Tulu

Amazon Stock Falls Sharply on Earnings. Spending Continues to Soar. -- Barrons.com

5. veebr 2026, 22:37 UTC

Market Talk

Woolworths's Profit Margin Likely Faces 2Q Squeeze -- Market Talk

5. veebr 2026, 22:11 UTC

Tulu

REA Group Lifts Dividend, Announces Buyback as 1H Profit Rises 9% -- Update

5. veebr 2026, 22:03 UTC

Tulu
Omandamised, ülevõtmised, äriostud

Amazon to Spend $200 Billion as It Accelerates AI Projects -- 4th Update

5. veebr 2026, 22:01 UTC

Tulu

Reddit Stock Jumps on Earnings. CFO Cites Modest AI Spending. -- Barrons.com

5. veebr 2026, 21:59 UTC

Market Talk
Omandamised, ülevõtmised, äriostud

What's Next For Rio Tinto, Glencore After Deal Talks Fail? -- Market Talk

5. veebr 2026, 21:51 UTC

Tulu
Omandamised, ülevõtmised, äriostud

Saylor's Strategy Posts $12 Billion Quarterly Loss on Bitcoin Selloff -- WSJ

5. veebr 2026, 21:50 UTC

Market Talk
Omandamised, ülevõtmised, äriostud

Basic Materials Roundup: Market Talk

5. veebr 2026, 21:49 UTC

Tulu

Why Google's Bad News Was Good News for Broadcom and Nvidia -- Barrons.com

5. veebr 2026, 21:45 UTC

Tulu

REA Group Lifts Dividend, Announces Buyback as 1H Profit Rises 9%

Võrdlus sarnastega

Hinnamuutus

Cytek Biosciences Inc Prognoos

Hinnasiht

By TipRanks

25.15% tõus

12 kuu keskmine prognoos

Keskmine 6.17 USD  25.15%

Kõrge 7.5 USD

Madal 5 USD

Põhineb 3 Wall Streeti analüütiku instrumendi Cytek Biosciences Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

3 ratings

1

Osta

2

Hoia

0

Müü

Tehniline skoor

By Trading Central

3.7 / 3.8Toetus ja vastupanu

Lühikene perspektiiv

Weak Bullish Evidence

Keskpikk perspektiiv

Bearish Evidence

Pikk perspektiiv

Bearish Evidence

Sentiment

By Acuity

23 / 352 Pingereas Tervishoid

Uudiste sentiment

Väga tugevad tõusu märgid

Volatiilsus

Alla keskmise

Uudismaht (RCV)

Keskmine

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Cytek Biosciences Inc

Cytek Biosciences, Inc., a cell analysis solutions company, provides cell analysis tools that facilitates scientific advances in biomedical research and clinical applications. It offers aurora and northern lights systems, which are spectrum flow cytometers that delivers cell analysis by utilizing the fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells; and aurora cell sorter system that leverages full spectrum profiling technology to further broaden potential applications across cell analysis; aurora CS systems; amnis imagestream imaging flow cytometers; guava muse cell analyzers; guava easycyte flow cytometers; and orion reagent cocktail preparation systems. The company also provides reagents and kits, including cFluor reagents that are fluorochrome conjugated antibodies used to identify cells of interest for analysis on its instruments, as well as 25-color immunoprofiling assay that provides turnkey solutions for identifying major human immune subpopulations for TBNK cells, monocytes, dendritic cells, and basophils. In addition, it offers automated micro-sampling system and automated sample loader system, an automated loaders to integrate seamlessly into the aurora and northern lights systems; SpectroFlo software that provides intuitive workflow from quality control to data analysis for aurora and northern lights systems; and customer support tools. The company serves pharmaceutical and biopharma companies, academic research centers, and clinical research organizations. It distributes its products through direct sales force and support organizations in North America, Europe, China, and the Asia-Pacific regions; and through distributors or sales agents in European, Latin American, and the Middle Eastern countries. The company was formerly known as Cytoville, Inc. and changed its name to Cytek Biosciences, Inc. in August 2015. Cytek Biosciences, Inc. was founded in 1992 and is headquartered in Fremont, California.
help-icon Live chat